Future-Proofing Pathology: Enhancing Drug Safety Evaluations
Deciphex is at the forefront of future-proofing pathology by improving drug safety evaluations through advanced AI models. In partnership with Novartis, we are developing next-generation unsupervised AI models that enhance the ability to detect lesions across multiple species. This collaboration is setting new standards for consistency and efficiency in nonclinical safety assessments, helping pharmaceutical companies make safer decisions earlier in the drug development process.
Improving Drug Safety with AI-Powered Lesion Detection
By leveraging unsupervised AI models, Deciphex enables faster and more precise detection of potential safety risks in preclinical studies. Our AI tools are designed to automatically detect lesions and abnormalities across a wide range of species, improving the accuracy of safety assessments and ensuring that unsafe compounds are identified before advancing to clinical trials.
Multispecies Lesion Detection
The partnership with Novartis is focused on developing AI that can identify lesions in multiple species commonly used in preclinical research. This multispecies capability improves the overall robustness of safety evaluations, ensuring that the AI is adaptable to various research environments and can deliver consistent results across different animal models.
Next-Generation of Pathology Foundation AI Models
By building next-generation AI models, Deciphex is helping to future-proof pathology. These models are trained on diverse datasets, enabling them to accurately detect a wide range of lesions and abnormalities, regardless of species or study type. The goal is to create an AI foundation that can evolve and adapt, ensuring its relevance and effectiveness in drug safety evaluations for years to come.
Enhancing Efficiency and Speed in Safety Evaluations
The integration of AI-driven lesion detection not only improves the consistency of safety assessments but also significantly reduces the time required to conduct these evaluations. With AI handling the routine detection tasks, pathologists can focus on target organs, resulting in faster decision-making and improved overall efficiency in the drug development pipeline.
Regulatory Acceptance of AI Models in Safety Evaluations
Deciphex, through our collaboration with Novartis, is leading the way in regulatory acceptance of AI models. By integrating advanced AI into safety evaluations, we improve precision, streamline decision-making, and enhance compliance. This forward-thinking approach ensures safer, more reliable drug safety assessments while staying ahead of regulatory demands.
Resources
Novartis/Deciphex Collaboration
